Abbott named industry leader for responsible and sustainable business for three consecutive years on the Dow Jones Sustainability Index (DJSI)

AbbottFor the third consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate responsibility and sustainability. As the Industry Group Leader in Health Care Equipment & Services, Abbott is the only U.S.-based company of the 24 companies recognized for leading their respective industry groups. The DJSI leaders are chosen from among 3,400 of the largest companies worldwide, including companies in developed and emerging markets. This is the 11th consecutive year that Abbott has been recognized for sustainability leadership through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.

"Our purpose at Abbott is to help people live the best and fullest lives they can," said Miles D. White, chairman and chief executive officer, Abbott. "It all comes down to keeping our promise, by striving to advance human health and happiness in all we do and by approaching every challenge with utmost respect and sensitivity to our world and its people."

In addition to being named a broader Industry Group Leader, Abbott also was the leader in its specific DJSI industry sector, Health Care Equipment & Supplies. Abbott earned the highest industry scores across all three areas of overall economic, environmental and social performance. The company's score of 88 was more than double the average score of 39 for other companies in the industry. Abbott's leading position was strengthened in 2015; the company's score increased five points from 83 to 88, compared to a two-point average decrease across the industry.

Abbott also achieved the top industry scores in 15 of DJSI's 23 specific economic, environmental and social criteria, including innovation management; strategy to improve access to drugs or products; operational eco-efficiency; corporate governance; supply chain management; health outcome contribution; human capital development; labor practice indicators and human rights; talent attraction and retention; stakeholder engagement; customer relationship management; risk and crisis management; tax strategy; bioethics; and corporate citizenship and philanthropy.

About Abbott's approach to citizenship
At Abbott, we see tremendous potential to make life better. This idea is at the core of our approach to global citizenship - creating a more responsible, sustainable and inclusive business that builds better lives and stronger communities around the world.

We focus on three priority areas that are most important for our business and the many people we serve: delivering product excellence, improving access and safeguarding the environment. By applying our science, products and expertise in these three areas, we're working to maximize the promise of human potential, around the world.

In addition to being included in the Dow Jones Sustainability Index for 11 years, Abbott has been named one of the 100 Best Corporate Citizens by Corporate Responsibility magazine for seven consecutive years.

About the Dow Jones Sustainability Index (DJSI)
Launched in 1999, the Dow Jones Sustainability Index (DJSI) is the first global index to track the leading sustainability-driven companies worldwide based on an analysis of financially material environmental, social and governance factors. The Dow Jones Sustainability Indices are maintained collaboratively by S&P Dow Jones Indices and RobecoSAM, the investment specialist focused exclusively on Sustainability Investing. RobecoSAM invited the world's largest 3,400 companies from developed and emerging markets to take part in its annual Corporate Sustainability Assessment.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical…

Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. ("Ono") announced today the three companies have entered into a clinical collaboration ag...

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...